article thumbnail

White paper reveals pathway for digital therapeutics use in Italy

pharmaphorum

A white paper has outlined a pathway that could allow Italy to realise the potential of digital therapeutics (DTx). The official journal of the Smith Kline Foundation, Tendenze Nuove, has published the paper entitled “Digital Therapeutics, an Opportunity for Italy” earlier this month.

article thumbnail

Italy eyes Digital Therapeutics

pharmaphorum

The recommendations for the Country’s pathway towards DTx are captured in the White Paper “Digital Therapeutics, an Opportunity for Italy” The official journal of the Smith Kline Foundation, Tendenze Nuove , published the White Paper “ Digital Therapeutics, an Opportunity for Italy ” on 13 January 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma must adapt to embrace the opportunities of a new-look NHS

pharmaphorum

A new focus on “place” and the introduction of medicines registers are among the proposals in a new government white paper on the future of NHS England. One surprise within the white paper was the introduction of the concept of medicines registries, says Thorne. “In Opportunities abound.

article thumbnail

Resolving challenges with product recovery in biopharma manufacturing

Pharmaceutical Technology

To learn more about how the 3M Harvest RC Chromatographic Clarifier is revolutionising biopharma production, download this specially commissioned white paper. “This can result in reductions in costs for our customers.”

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

In 2020, the FDA released a guidance document for the industry with recommendations for sponsors developing gene therapies for rare diseases. This document delved into aspects related to manufacturing, preclinical, and clinical trial design for all phases of clinical development.

article thumbnail

Drugmakers pledge shorter launch times for drugs in EU

pharmaphorum

“The industry has concerns regarding the use of regulatory tools designed for medicines authorisation being applied to address availability issues that are within the remit of member states,” says the white paper. . — EFPIA (@EFPIA) April 11, 2022.

article thumbnail

Bottlenecks in buffer preparation – solving downstream issues for upstream gains

European Pharmaceutical Review

To enable this, the design documentation, whitepaper and testing results have been made available open source to all, 6 with the hope that we will see this technology become the standard for buffer preparation as we look to create further efficiencies in the future. . References. cited 2022Nov] Available from: [link].